Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.97 |
| ▸ | RARB | P10826 | 4/20 | 0.90 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.85 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.70 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778285 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL371494 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL503568 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL10777726 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL3625733 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1163918 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1322922 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL7470745 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1469965 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL503367 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-11419803-B2 | Skin darkening composition | CONOPCO, INC. (US) | 2022-08-23 | — | — | US | claimed |
| US-20200330349-A1 | A Skin Darkening Composition | CONOPCO, INC., D/B/A UNILEVER (US) | 2020-10-22 | — | — | US | claimed |
| EP-3720414-A1 | A SKIN DARKENING COMPOSITION | Unilever N.V. (NL) | 2020-10-14 | — | — | EP | claimed |
| WO-2019110212-A1 | A SKIN DARKENING COMPOSITION | UNILEVER N.V. (NL) | 2019-06-13 | — | — | WO | claimed |
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-0868535-B9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2007-05-09 | — | — | EP | claimed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330349-A1 | A Skin Darkening Composition | CUTA, TYR, GABBR1 | TP53 4613/4885TSHR 3492/4885PLA2G4B 1219/4885 |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | TP53 95/4885TSHR 4107/4885PLA2G4B 2950/4885 |
| US-11419803-B2 | Skin darkening composition | CUTA, TYR, CYP2A13 | TP53 4744/4885TSHR 3304/4885PLA2G4B 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.